Transparency notifications BlackRock, Inc.
- 3 Notifications referring to situation on 27, 28 and 29 March 2019
- Threshold crossed: 5%
- Latest holding: 5,38 %
Brussels (Belgium), 2 April 2019 – 20:00 (CEST) – regulated information
1. Summary of the notifications
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 3 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 28, 29 March and 1 April 2019 respectively.
In the first and the third notification, BlackRock, Inc., has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its holding in UCB shares has increased and has crossed the 5% threshold on 27 March 2019 and 29 March 2019 respectively.
In the second notification, BlackRock, Inc., has notified that, following a disposal of UCB shares with voting rights by its affiliates, its holding in UCB shares has decreased and has crossed downwards the 5% threshold on 28 March 2019.
On 27 March 2019, BlackRock, Inc. (taking into account the holding of its affiliates) Inc. owned 9 757 931 UCB shares with voting rights (versus 9 575 676 shares in its previous notification), representing 5.02% of the total number of shares issued by the company (194 505 658) (versus 4.92% in its previous notification), as well as 586 717 equivalent financial instruments (versus 598 149 in its previous notification) representing 0.30% of the total number of shares issued by the company (versus 0.31% in its previous notification).
On 29 March 2019, BlackRock, Inc. (taking into account the holding of its affiliates) 9 897 684 UCB shares with voting rights, representing 5.09% of the total number of shares issued by the company, as well as 569 052 equivalent financial instruments, representing 0.29% of the total number of shares issued by the company.
2. Content of the notifications
2.1 The information mentioned hereafter was identical in all notifications:
- Notification by: A parent undertaking or a controlling person.
- Reason for the notification: Acquisition or disposal of voting securities or voting rights.
- Persons subject to the notification requirement:
- Threshold crossed (in %): 5%
- Denominator: 194 505 658.
- Chain of controlled undertakings through which the holding is effectively held:
Please see the full chain of control in the ‘Chain of Control’ tab.
2.2 The first transparency notification dated 28 March 2019 included the following specific information:
- Date on which the threshold is crossed: 27 March 2019.
- Notified details:
- Additional information:
The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 5%.
2.3. The second transparency notification dated 29 March 2019 includes the following specific information:
- Date on which the threshold is crossed: 28 March 2019.
- Notified details:
- Additional information:
The disclosure obligation arose due to total holdings for BlackRock, Inc. going below 5%. The filing is due to voting rights attached to shares for BlacRock, Inc. going below 5%. In heading 10), (A) however, the forms displays it as remaining at 5%. Please note this is due to the rounding of the form.
2.4. The third transparency notification dated 1 April 2019 includes the following specific information:
- Date on which the threshold is crossed: 29 March 2019.
- Notified details:
- Additional information:
The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 5%.
3. Further information
This press release and the detailed transparency notifications are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.
Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Asset Download
Stay up-to-date on the latest news and information from UCB